small molecule

TYBOST

COBICISTAT

Loss of exclusivityApril 2033latest FDA-listed patent expiry
CompanyGilead SciencesView the full company profile on CliffBio

Drug detail

Brand nameTYBOST
Active ingredientCOBICISTAT
Strength90MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 2025
Marketing statusDISCN

Listed patents

PatentExpiresType
10039718*PEDApril 2033
10039718October 2032product
8148374*PEDMarch 2030
8148374September 2029substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TYBOST patent cliff — loss of exclusivity April 2033 | CliffBio